Abstract:Highlights • FGF21 expression in hepatocytes and macrophages is upregulated during sepsis. • FGF21 inhibits proinflammatory macrophage activation by resuming autophagy flux to ameliorate septic liver injury. • FGF21 accelerates autolysosome degradation via mTOR signaling, while it has no effect on autophagosome formation induced by LPS via ERK and JNK signaling pathways. • FGF21 promotes p62-dependent autophagic degradation of HIF-1α in macrophages by enhancing the interaction between p62 and HIF-1α. Introduction Sepsis, a systemic immune syndrome caused by severe trauma or infection, poses a substantial threat to the health of patients worldwide. The progression of sepsis is heavily influenced by septic liver injury, which is triggered by infection and cytokine storms, and has a significant impact on the tolerance and prognosis of septic patients. The objective of our study is to elucidate the biological role and molecular mechanism of fibroblast growth factor 21 (FGF21) in the process of sepsis. Objectives This study was undertaken in an attempt to elucidate the function and molecular mechanism of FGF21 in therapy of sepsis. Methods Serum concentrations of FGF21 were measured in sepsis patients and septic mice. Liver injury was compared between mice FGF21 knockout (KO) mice and wildtype (WT) mice. To assess the therapeutic potential, recombinant human FGF21 was administered to septic mice. Furthermore, the molecular mechanism of FGF21 was investigated in mice with myeloid-cell specific HIF-1α overexpression mice (LyzM-Cre DIO-HIF-1α ) and myeloid-cell specific Atg7 knockout mice ( Atg7 △mye ). Results Serum level of FGF21 was significantly increased in sepsis patients and septic mice. Through the use of recombinant human FGF21 (rhFGF21) and FGF21 KO mice, we found that FGF21 mitigated septic liver injury by inhibiting the initiation and propagation of inflammation. Treatment with rhFGF21 effectively suppressed the activation of proinflammatory macrophages by promoting macroautophagy/autophagy degradation of hypoxia-inducible factor-1α (HIF-1α). Importantly, the therapeutic effect of rhFGF21 against septic liver injury was nullified in LyzM-Cre DIO-HIF-1α mice and Atg7 △mye mice. Conclusions Our findings demonstrate that FGF21 considerably suppresses inflammation upon septic liver injury through the autophagy/ HIF-1α axis. Graphical abstract Schematic showing that FGF21 alleviates septic liver injury by inhibiting proinflammatory activation of macrophages by promoting autophagic degradation of HIF-1α. Download : Download high-res image (242KB) Download : Download full-size image

FGF21 alleviates acute liver injury by inducing the SIRT1‐autophagy signalling pathway

Fibroblast growth factor 21 alleviates acetaminophen induced acute liver injury by activating Sirt1 mediated autophagy

Fibroblast growth factor 21 alleviates acute pancreatitis via activation of the Sirt1‐autophagy signalling pathway

Fibroblast Growth Factor 21 Relieves Lipopolysaccharide-Induced Acute Lung Injury by Suppressing JAK2/STAT3 Signaling Pathway

FGF21 protects against ischaemia reperfusion injury in normal and fatty livers

Fibroblast Growth Factor 21 Ameliorates Cholestatic Liver Injury Via a Hepatic FGFR4-JNK Pathway.

FGF21 modulates immunometabolic homeostasis via the ALOX15/15-HETE axis in early liver graft injury

FGF21 ameliorates septic liver injury by restraining proinflammatory macrophages activation through the autophagy/HIF-1α axis

FGF21 Ameliorates Nonalcoholic Fatty Liver Disease by Inducing Autophagy

[FGF21 inhibits lipid accumulation and inflammation induced by palmitate in human hepatocytes via SIRT1 pathway].

Fibroblast Growth Factor-21 Ameliorates Hepatic Encephalopathy by Activating the STAT3-SOCS3 Pathway to Inhibit Activated Hepatic Stellate Cells.

Fibroblast growth factor (FGF21) protects mouse liver against D-galactose-induced oxidative stress and apoptosis via activating Nrf2 and PI3K/Akt pathways

Role of fibroblast growth factor 21 in Pathogenesis of alcoholic liver fibrosis

Cardioprotective effects of fibroblast growth factor 21 against doxorubicin-induced toxicity via the SIRT1/LKB1/AMPK pathway

Fibroblast growth factor 21 attenuates pulmonary ischemia/reperfusion injury via inhibiting endoplasmic reticulum stress-induced ferroptosis though FGFR1/PPARδ signaling pathway

Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling

FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis

SIRT1 Mediates Effects of FGF21 to Ameliorate Cisplatin-Induced Acute Kidney Injury

Aberrant FGFR4 Signaling Worsens Nonalcoholic Steatohepatitis in FGF21KO Mice

Fibroblast Growth Factor 21 is Regulated by the IRE1α-XBP1 Branch of the Unfolded Protein Response and Counteracts Endoplasmic Reticulum Stress-Induced Hepatic Steatosis.

Aberrant FGF15/FGFR4 Signaling Worsens Nonalcoholic Steatohepatitis Severity in FGF21KO Mice